Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Dermatologic 2Sarcoma 1Head & Neck 1Breast 1

Conditions

Breast Neoplasms 5Triple Negative Breast Neoplasms 3Sarcoma 1Mycosis Fungoides 1Melanoma 1Inflammatory Breast Neoplasms 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Merkel Cell 1Carcinoma, Ductal, Breast 1Carcinoma, Ductal 1Breast Carcinoma In Situ 1

Interventions

pembrolizumab 3talimogene laherparepvec 1spartalizumab 1nanocis 1fludarabine 1avelumab 1atezolizumab 1aldesleukin 1Technetium-99 1TTI-621 1Radiation 1Proton Pump Inhibitors 1Nivolumab 1Lasers 1Ipilimumab 1Interleukin-2 1Infracyanine green 1Indocyanine Green 1Hydrocortisone 1Cyclophosphamide 1Bleomycin 1Antineoplastic Protocols 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Squamous Cell × talimogene laherparepvec × Breast × Clear all
NCT02890368 2023-04-05

Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides

Pfizer

Phase 1 Terminated
56 enrolled
BreastDermatologicLymphoidSarcoma

Breast Neoplasms, Carcinoma, Squamous Cell, Melanoma, Mycosis Fungoides, Sarcoma, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡